Oil Spill Disaster Workers Seek Relief with filt-R

Thursday, June 10, 2010 Environmental Health J E 4

SEATTLE, June 10 The Gulf Oil Region is suffering the airborne effects from the largest oil spill in U.S. history. Smelling like sulphur, the crude oil's strong scent has drifted past the infested beaches. Local residents and cleanup personnel struggle to shield themselves from the odors. Only full respirators were doing the job. It's not only an unpleasant smell but it may have unknown health consequences, and workers have been left on their own to find protection.

That's where the Seattle-based filt-R corporation comes in. "We get dozens of calls from workers in the Gulf," according to filt-R manager, Brian Swain. "They're looking for some relief from the fumes."

Independent workers and agents have reached out to filt-R through their website looking for a positive alternative.

"You don't expect these events to be connected, but we got similar calls and orders over concerns about the Icelandic Volcano eruptions," Brian continues. "People need solutions and they like filt-R."

"Normally filt-R is used by commuters to protect against city pollution, but now we see new uses for our mask," claims David Buksh, filt-R President. "filt-R is now used by civilians and workers alike near the spill sites to help filter noxious fumes." The filt-R is $29.95 with replacement filters for less than $5. Available globally via

"We're trying our best to get filt-R's down to folks," says Mr. Swain. "We're looking for distribution to help with demand."

This press release was issued through eReleases(R). For more information, visit eReleases Press Release Distribution at

Contact: David Buksh 206.931.6185



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Synutra Reports Financial Results for the Fourth Q...
PurGenesis Initiates Phase 2a Trial for the Treatm...